Inventaire - your friends and communities are your best library - Inventaire

A small molecule-kinase interaction map for clinical kinase inhibitors

published in: Nature Biotechnology

date of publication: 2005-03

language: English

main subject: erlotinib

Cites articles 36

Date

Title

Authors

2004-05-20

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Daniel Haber, David C. Christiani
2004-06-04

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

Heidi Greulich, Stacey Gabriel, Matthew Meyerson, Pasi A Jänne, Titus J Boggon
2004-09-07

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Harold E. Varmus, William Pao, Lucinda Fulton, Elaine Mardis, Mark G Kris, Valerie W Rusch, Katerina Politi
2004-07-16

Overriding imatinib resistance with a novel ABL kinase inhibitor
2004-03-01

Kinomics-structural biology and chemogenomics of kinase inhibitors and targets
2004-04-20

Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo

Allan B. Dietz, Mark R Litzow
2004-06-01

Novel agents in the treatment of lung cancer: conference summary statement

Giuseppe Giaccone, Roy S. Herbst
2003-09

Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity

Giovanna Scapin, Stephen J O'Keefe
2003-04-01

The specificities of protein kinase inhibitors: an update
2003-04-01

Issues and progress with protein kinase inhibitors for cancer treatment
2003-09-01

p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases
2003-12-10

An efficient proteomics method to identify the cellular targets of protein kinase inhibitors

Matthew Cotten
2003-02-01

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias

Carlo Gambacorti-Passerini, Leonardo Scapozza
2003-03-01

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

George Q. Daley
2003-04-01

Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase
2002-04

Protein kinases--the major drug targets of the twenty-first century?
2002-12-06

The protein kinase complement of the human genome

Gerard Manning
2002-04

Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site
2002-06-01

Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer
2002-06-01

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)

Ifor R. Williams
2002-02-01

Perspectives on the development of a molecularly targeted agent

Brian Druker
2002-02-01

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study.
2002-08

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
2002-05-01

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance
2002-07-29

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop
2002-09-05

Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases

Michael Hallek
2002-03-01

The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations

Cem Akin, Dean D. Metcalfe
2001-11-01

SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase

Brion W Murray
2001-08-03

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
2000-09-01

Combinatorial chemoprevention of intestinal neoplasia

Bert Vogelstein, Kenneth W Kinzler
1999-10-01

Display cloning: functional identification of natural product receptors using cDNA-phage display
1998-07-24

Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors

Sung-Hou Kim

Article - wd:Q29617451

Welcome to Inventaire

the library of your friends and communities

you are offline